Purdue Pharma bankruptcy plan, which would give Sackler family immunity, moves forward

A controversial bankruptcy plan involving Purdue Pharma, which would shield the Sackler family from litigation tied to the opioid crisis, has moved forward.

A controversial bankruptcy plan involving OxyContin maker Purdue Pharma, which would shield the Sackler family from litigation tied to the opioid crisis, moved forward Thursday. A federal bankruptcy court judge in White Plains, New York, allowed Purdue to begin soliciting support for its Chapter 11 reorganization plan, which would dissolve the drug company and reestablish it as a public trust. Over 600,000 claimants will now start to receive ballots regarding the plan. Purdue filed for Chapter 11 protection in 2019 as it faced thousands of lawsuits across the country over its aggressive marketing of OxyContin and other opioid products. The company said the reorganization plan would deliver more than $10 billion in value to communities ravaged by the opioid epidemic and provide millions of doses of opioid addiction treatment and overdose reversal medications.